CIP
HAE icon

Champlain Investment Partners’s Haemonetics HAE Stock Holding History

Champlain Investment Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,137,670
Closed -$37.1M – 143
2014
Q1 		$37.1M Sell
1,137,670
-150,560
-12% -$5.75M 0.64% 76
2013
Q4 		$54.3M Buy
1,288,230
+209,965
+19% +$8.64M 0.96% 35
2013
Q3 		$43M Buy
+1,078,265
New +$45.2M 0.82% 52

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Champlain Investment Partners's HAE Position: Q2 2014 in Review

Champlain Investment Partners sold out of Haemonetics (HAE) in Q2 2014, closing a stake of 1,137,670 shares — an estimated $37.1M sold.

Champlain Investment Partners first reported a position in HAE in Q3 2013 and held it in 3 quarters. The position peaked at $54.3M in Q4 2013. 175 funds tracked by Wall St. Rank hold HAE as of Q2 2014.

  • Champlain Investment Partners reported no remaining Haemonetics position as of Q2 2014 after selling out during the quarter.
  • Champlain Investment Partners sold 1,137,670 Haemonetics shares in Q2 2014, an estimated $37.1M.
  • Champlain Investment Partners first reported a position in Haemonetics in Q3 2013 and held it in 3 quarters.
  • Champlain Investment Partners's Haemonetics position peaked at $54.3M in Q4 2013.
  • 175 funds tracked by Wall St. Rank held Haemonetics as of Q2 2014.

Based on Champlain Investment Partners's 13F filing for Q2 2014, filed 13 Aug 2014.